/ CORRECTION - NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference

/ CORRECTION - NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference

ID: 322745

(firmenpresse) - AMES, IA -- (Marketwired) -- 12/05/13 -- In the news release, "NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference," issued earlier today by NewLink Genetics Corporation (NASDAQ: NLNK), we are advised by the company that the conference date in the first paragraph should read "Tuesday, December 10, 2013" rather than "Tuesday, December 11, 2013" as originally issued. The headline has also been updated. Complete corrected text follows.



AMES, IA -- Dec 5, 2013 -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, announced today that Charles J. Link, Jr., M.D., NewLink's Founder and Chief Executive Officer, is scheduled to present at the Oppenheimer 24th Annual Healthcare Conference in New York, on Tuesday, December 10, 2013 at 1:35 p.m. ET.



NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for patients with cancer. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. For more information please visit . Patient information is available at .



Gordon Link
Chief Financial Officer
515-598-2925




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference PBMI Research Shows Drug Benefit Design Approaches Consistent With 2012
Bereitgestellt von Benutzer: Marketwired
Datum: 05.12.2013 - 17:06 Uhr
Sprache: Deutsch
News-ID 322745
Anzahl Zeichen: 0

contact information:
Town:

AMES, IA



Kategorie:

Hospitals, Facilities and Providers



Diese Pressemitteilung wurde bisher 335 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"/ CORRECTION - NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

NewLink Genetics Corporation (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von NewLink Genetics Corporation



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z